Avadel Pharmaceuticals plc (AVDL) Research

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.

Market snapshot

Symbol
AVDL
Price
$21.64
Day change
0.00%
Market cap
$2.1B
P/E ratio
108200.00x
52-week range
6.38-23.57
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Analyst price target
$21.43

Peer companies

  • Alvotech (ALVO)
  • ANI Pharmaceuticals, Inc. (ANIP)
  • BGM Group Ltd. (BGM)
  • Evotec SE (EVO)
  • Guardian Pharmacy Services, Inc. (GRDN)
  • Pediatrix Medical Group, Inc. (MD)
  • Organon & Co. (OGN)
  • Phibro Animal Health Corporation (PAHC)

Recent insider activity

  • Weiss Asset Management LP — S-Sale (11112052 shares) on 2026-02-13
  • Weiss Asset Management LP — trade (0 shares) on 2026-02-11
  • Rodriguez Susan — D-Return (300000 shares) on 2026-02-12
  • Thornton Peter J. — D-Return (42000 shares) on 2026-02-12
  • Thornton Peter J. — D-Return (42000 shares) on 2026-02-12

Open Avadel Pharmaceuticals plc (AVDL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.